Anti-BRCA1 (phospho S1423) antibody (ab90528)


  • Product nameAnti-BRCA1 (phospho S1423) antibody
    See all BRCA1 primary antibodies
  • Description
    Rabbit polyclonal to BRCA1 (phospho S1423)
  • Tested applicationsSuitable for: WB, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Dog, Pig, Chimpanzee, Macaque Monkey, Gorilla, Orangutan
  • Immunogen

    Synthetic peptide conjugated to KLH derived from within residues 1400 - 1500 of Human BRCA1, phosphorylated at S1423.

  • Positive control
    • This antibody gave a positive signal in Irradiated HeLa Whole Cell Lysate.



Our Abpromise guarantee covers the use of ab90528 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Detects a band of approximately 208 kDa (predicted molecular weight: 208 kDa).
ICC/IF Use a concentration of 5 µg/ml.


  • FunctionE3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks.
  • Tissue specificityIsoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.
  • PathwayProtein modification; protein ubiquitination.
  • Involvement in diseaseDefects in BRCA1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Note=Mutations in BRCA1 are thought to be responsible for 45% of inherited breast cancer. Moreover, BRCA1 carriers have a 4-fold increased risk of colon cancer, whereas male carriers face a 3-fold increased risk of prostate cancer. Cells lacking BRCA1 show defects in DNA repair by homologous recombination.
    Defects in BRCA1 are a cause of susceptibility to breast-ovarian cancer familial type 1 (BROVCA1) [MIM:604370]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. Note=Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer.
    Defects in BRCA1 are a cause of genetic susceptibility to ovarian cancer [MIM:113705].
  • Sequence similaritiesContains 2 BRCT domains.
    Contains 1 RING-type zinc finger.
  • DomainThe BRCT domains recognize and bind phosphorylated pSXXF motif on proteins. The interaction with the phosphorylated pSXXF motif of FAM175A/Abraxas, recruits BRCA1 at DNA damage sites.
    The RING-type zinc finger domain interacts with BAP1.
  • Post-translational
    Phosphorylation at Ser-308 by STK6/AURKA is required for normal cell cycle progression from G2 to mitosis. Phosphorylated in response to IR, UV, and various stimuli that cause checkpoint activation, probably by ATM or ATR.
    Autoubiquitinated, undergoes 'Lys-6'-linked polyubiquitination. 'Lys-6'-linked polyubiquitination does not promote degradation.
  • Cellular localizationCytoplasm; Nucleus. Localizes at sites of DNA damage at double-strand breaks (DSBs) and recruitment to DNA damage sites is mediated by the BRCA1-A complex.
  • Information by UniProt
  • Database links
  • Alternative names
    • BRCA 1 antibody
    • BRCA1 antibody
    • BRCA1/BRCA2 containing complex subunit 1 antibody
    • BRCA1/BRCA2-containing complex, subunit 1 antibody
    • BRCA1_HUMAN antibody
    • BRCAI antibody
    • BRCC 1 antibody
    • BRCC1 antibody
    • Breast and ovarian cancer susceptibility protein 1 antibody
    • Breast Cancer 1 antibody
    • Breast Cancer 1 Early Onset antibody
    • Breast cancer type 1 susceptibility protein antibody
    • BROVCA1 antibody
    • IRIS antibody
    • PNCA4 antibody
    • PPP1R53 antibody
    • Protein phosphatase 1 regulatory subunit 53 antibody
    • PSCP antibody
    • RING finger protein 53 antibody
    • RNF53 antibody
    see all

Anti-BRCA1 (phospho S1423) antibody images

  • All lanes : Anti-BRCA1 (phospho S1423) antibody (ab90528) at 1 µg/ml

    Lane 1 : Irradiated HeLa Whole Cell Lysate
    Lane 2 : Irradiated HeLa Whole Cell Lysate with Immunising Peptide at 1 µg/ml
    Lane 3 : Irradiated HeLa Whole Cell Lysate with Non-Modified Control Peptide at 1 µg/ml

    Lysates/proteins at 10 µg per lane.

    Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
    developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 208 kDa
    Observed band size : 208 kDa
    Additional bands at : 110 kDa,140 kDa,160 kDa. We are unsure as to the identity of these extra bands.

    Exposure time : 3 minutes
  • ICC/IF image of ab90528 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab90528, 5µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM. This antibody also gave a positive result in 4% PFA fixed (10 min) HepG2 cells at 5µg/ml.
  • ab90528 (1/200) staining BRCA1 (phospho S1423) in HeLa cells (green). Cells were fixed in paraformaldehyde, permeabilised with 0.5% Triton X100/PBS and counterstained with DAPI in order to highlight the nucleus (red). For further experimental details please refer to Abreview.

    See Abreview

References for Anti-BRCA1 (phospho S1423) antibody (ab90528)

ab90528 has not yet been referenced specifically in any publications.

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (HeLa)
Specification HeLa
Fixative Paraformaldehyde
Permeabilization Yes - 0.5% Triton-X100 in PBS

Dr. Kirk McManus

Verified customer

Submitted Feb 10 2012